Azacytidine plus olaparib for relapsed acute myeloid leukaemia, ineligible for intensive chemotherapy, diagnosed with a synchronous malignancy

Patients with relapsed/refractory acute myeloid leukaemia (AML), ineligible for intensive chemotherapy and allogeneic stem cell transplantation, have a dismal prognosis. For such cases, hypomethylating agents are a viable alternative, but with limited success. Combination chemotherapy using a hypome...

Descripción completa

Detalles Bibliográficos
Autores principales: Iluta, Sabina, Pasca, Sergiu, Gafencu, Grigore, Jurj, Ancuta, Terec, Andreea, Teodorescu, Patric, Selicean, Cristina, Jitaru, Ciprian, Preda, Alexandra, Cenariu, Diana, Constantinescu, Catalin, Iordache, Maria, Tigu, Bogdan, Munteanu, Raluca, Feder, Richard, Dima, Delia, Zdrenghea, Mihnea, Gulei, Diana, Ciuleanu, Tudor‐Eliade, Tomuleasa, Ciprian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8406486/
https://www.ncbi.nlm.nih.gov/pubmed/34132464
http://dx.doi.org/10.1111/jcmm.16513

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8406486/
https://www.ncbi.nlm.nih.gov/pubmed/34132464
http://dx.doi.org/10.1111/jcmm.16513

Ejemplares similares